Tradestie Institutional Equity Comparison Engine

ZLAB vs IONS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IONS Overall Edge

IONS Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ionis Pharmaceuticals, Inc. Common Stock (IONS) driven by superior Valuation, Growth & Margin while ZLAB counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ZLAB trades at N/M Forward P/E with -63.0% operating margin (-6.8% YoY revenue) versus IONS at 90.9x Forward P/E and -58.8% operating margin (+54.9% YoY). In options structure, ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro) against IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner IONS
ZLAB N/M vs IONS 90.9x Fwd P/E
Growth & Margin Winner IONS
Op Margin -63.0% vs -58.8% ยท YoY -6.8% vs +54.9%
Momentum & Technical Winner ZLAB
1Y +9.2% vs -59.1% ยท 52W Pos 60% vs 2%
Options & Structure Winner ZLAB
UNCLASSIFIED (58th %ile IV) vs BREAKDOWN (17th %ile IV)
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.74
-3.5% 1D
Market Cap $3.0B
1M Return +2.37%
1Y Return +9.25%
Forward P/E N/M
Unified AI Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
1M Return -33.48%
1Y Return -59.1%
Forward P/E 90.9x
Unified AI Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZLAB +9.25% IONS -59.1% Spread: +68.35 pp (ZLAB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ZLAB TTM Op. Margin: -63.0% IONS TTM Op. Margin: -58.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs IONS. Trailing 12-month operating profitability (ZLAB -63.0% vs IONS -58.8%) and valuation multiples (ZLAB N/M vs IONS 90.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZLAB (4) vs IONS (6)
Institutional Metric ZLAB IONS Criterion Row Winner
Market Capitalization Scale $3.0B $4.7B Larger Scale IONS
Trailing P/E Ratio Valuation N/M 90.9x Lower Multiple IONS
Forward P/E Ratio Valuation N/M 90.9x Lower Multiple IONS
Revenue Growth (YoY) Growth -6.8% +54.9% Higher Growth IONS
Operating Margin (TTM) Profitability -63.0% -58.8% Higher Margin IONS
Net Profit Margin Profitability -44.9% -56.9% Higher Margin ZLAB
Return on Equity (ROE) Capital Efficiency -30.0% -108.0% Higher ROE ZLAB
52-Week Range Position Momentum 60% ($16โ€“$29) 2% ($27โ€“$87) Stronger Trend ZLAB
Beta / 30D Volatility Risk Regime 1.19ฮฒ ยท 78% Vol 0.18ฮฒ ยท 86% Vol Lower Realized Risk ZLAB
Unified Institutional Score Composite Signal 47.4 / 100 (HOLD) 63.9 / 100 (BUY) Higher Composite IONS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZLAB vs IONS Buy Guide
ZLAB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 58th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ZLAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IONS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZLAB nor IONS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.